Related Experiment Video

Updated: May 9, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets

Ramiro Iglesias-Bartolome1, Daniel Martin, J Silvio Gutkind

  • 1Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, MD 20892-4330, USA.

Cancer Discovery
|July 13, 2013
PubMed
Abstract

Insights

This study reveals the head and neck squamous cell carcinoma (HNSCC) mutational landscape, identifying key molecular pathways and actionable targets like the PI3K/mTOR pathway for novel cancer therapies.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Head and neck squamous cell carcinomas (HNSCC) represent a significant global health challenge.
  • Understanding the genomic and epigenetic alterations in HNSCC is crucial for developing effective treatments.

Purpose of the Study:

  • To elucidate the emerging mutational landscape of HNSCC.
  • To identify novel actionable cancer drivers and predictive biomarkers for targeted therapies.
  • To investigate the molecular pathways driving HNSCC development and progression.

Main Methods:

  • Genomic profiling of HNSCC samples.
  • Epigenetic alteration analysis.
  • Pathway analysis to identify key molecular alterations.

Main Results:

  • Genomic alterations in HNSCC converge on specific molecular pathways.
  • Identified cell-cycle deregulation, genomic instability, and cell differentiation defects.
  • Aberrant phosphoinositide 3-kinase (PI3K)/mTOR pathway activation was frequently observed.

Conclusions:

  • The identified molecular alterations provide novel therapeutic targets for HNSCC.
  • HNSCC is responsive to PI3K/mTOR inhibitors due to pathway activation.
  • This research paves the way for targeted therapies and improved patient outcomes.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...